0001213900-24-062647.txt : 20240718 0001213900-24-062647.hdr.sgml : 20240718 20240718175300 ACCESSION NUMBER: 0001213900-24-062647 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240523 FILED AS OF DATE: 20240718 DATE AS OF CHANGE: 20240718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gottardis Marco CENTRAL INDEX KEY: 0002030962 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40427 FILM NUMBER: 241125642 MAIL ADDRESS: STREET 1: C/O NKGEN BIOTECH, INC. STREET 2: 3001 DAIMLER ST. CITY: SANTA ANA STATE: CA ZIP: 92701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NKGen Biotech, Inc. CENTRAL INDEX KEY: 0001845459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3001 DAIMLER ST, CITY: SANTA ANA STATE: CA ZIP: 92705 BUSINESS PHONE: (949) 396-6830 MAIL ADDRESS: STREET 1: 3001 DAIMLER ST, CITY: SANTA ANA STATE: CA ZIP: 92705 FORMER COMPANY: FORMER CONFORMED NAME: Graf Acquisition Corp. IV DATE OF NAME CHANGE: 20210210 4 1 ownership.xml X0508 4 2024-05-23 0 0001845459 NKGen Biotech, Inc. NKGN 0002030962 Gottardis Marco NKGEN BIOTECH, INC. 3001 DAIMLER STREET SANTA ANA CA 92705 1 0 0 0 0 Stock Option (right to buy) 2.00 2024-07-11 4 A 0 300000 0.00 A Common Stock 300000 16667 D On July 11, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning July 11, 2024, and ending July 11, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. See Exhibit 24 - Power of Attorney /s/ Pierre Gagnon as Attorney-in-Fact 2024-07-18 EX-24.1 2 ea020968001ex24-1_nkgen.htm POWER OF ATTORNEY

Exhibit 24.1

 

POWER OF ATTORNEY

 

The undersigned constitutes and appoints Jeremy Spankowski, Robbie Oakes, Jesse Dowdle, Mike Blankenship and Pierre Gagnon, or any of them acting singly, as the undersigned’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned’s name, place and stead, to:

 

1.        prepare, sign, and submit to the Securities and Exchange Commission (the “SEC”) on its Electronic Data Gathering, Analysis, and Retrieval Filer Management website a Form ID application, including any amendments and exhibits thereto, and any other related documents as may be necessary or appropriate, to obtain from the SEC access codes to permit filing on the SEC’s EDGAR system, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each act and thing requisite and necessary to be done as required by any rule or regulation of the SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, may lawfully do or cause to be done by virtue hereof; and

 

2.       sign any and all SEC statements of beneficial ownership of securities of NKGen Biotech, Inc. (the “Company”) on Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, as amended, and any amendments thereto, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, the Company and any stock exchange on which any of the Company’s securities are listed, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each act and thing requisite and necessary to be done under said Section 13 and Section 16(a), as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, may lawfully do or cause to be done by virtue hereof.

 

A copy of this power of attorney shall be filed with the SEC.  The authorization set forth above shall continue in full force and effect until the undersigned revokes such authorization by written instructions to the attorneys-in-fact.

 

The authority granted hereby shall in no event be deemed to impose or create any duty on behalf of the attorneys-in-fact with respect to the undersigned’s obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5 with the SEC. 

 

Dated: July 12, 2024

 

  By: /s/ Marco Gottardis
  Name:  Marco Gottardis